GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Current Accrued Expense

Paratek Pharmaceuticals (FRA:N4CN) Current Accrued Expense : €25.7 Mil (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Current Accrued Expense?

Paratek Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2023 was €25.7 Mil.

Paratek Pharmaceuticals's quarterly Current Accrued Expense increased from Dec. 2022 (€18.8 Mil) to Mar. 2023 (€20.3 Mil) and increased from Mar. 2023 (€20.3 Mil) to Jun. 2023 (€25.7 Mil).

Paratek Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2020 (€10.7 Mil) to Dec. 2021 (€12.8 Mil) and increased from Dec. 2021 (€12.8 Mil) to Dec. 2022 (€18.8 Mil).


Paratek Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Paratek Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Current Accrued Expense Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.39 8.21 10.72 12.84 18.76

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.43 20.23 18.76 20.27 25.67

Paratek Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Paratek Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (FRA:N4CN) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines